Summit Therapeutics price target raised to $33 from $30 at Clear Street

Clear Street raised the firm’s price target on Summit Therapeutics (SMMT) to $33 from $30 and keeps a Buy rating on the shares following the Q2 report. The firm views the earnings print as “largely uneventful” with no fundamental changes on Summit’s research and development programs. Clear Street continues to view ivonescimab as the “front-runner in a novel class of medicines with several multi-billion-dollar oncology opportunities.”